Skip to main content
Year archive

Kamada Ltd. — 2020 filings

All 60 regulatory filings released by Kamada Ltd. (KMDA) in 2020, sourced directly from the official regulator.

60 Filings
2020 Period
2020 filings (60)
Filing Released Lang
MoU with the Employees’ Committee detailing the understandings reached with respect to severance remuneration as a result of the transfer of Glassia® manufacturing to Takeda
Regulatory Filings
2020-12-29 English
MoU with the Employees’ Committee detailing the understandings reached with respect to severance remuneration as a result of the transfer of Glassia® manufacturing to Takeda
Regulatory Filings
2020-12-29 English
Kamada Added to the NASDAQ Biotechnology Index
Regulatory Filings
2020-12-21 English
Kamada Added to the NASDAQ Biotechnology Index
Report Publication Announcement
2020-12-21 English
announce receipt of a notice of Labor Dispute from Employee’s Committee
Regulatory Filings
2020-12-15 English
announce receipt of a notice of Labor Dispute from Employee’s Committee
Regulatory Filings
2020-12-15 English
Notice of Results of the 2020 Annual General Meeting of Shareholders held on December 10, 2020
AGM Information
2020-12-10 English
Notice of Results of the 2020 Annual General Meeting of Shareholders held on December 10, 2020
AGM Information
2020-12-10 English
6K: Financial Statements as of September 30, 2020 (Unaudited)
Interim / Quarterly Report Q3 2020
2020-11-12 English
6K: Financial Statements as of September 30, 2020 (Unaudited)
Report Publication Announcement
2020-11-12 English
Third Quarter Ended September 30, 2020
Earnings Release 9M 2020
2020-11-11 English
Third Quarter Ended September 30, 2020
Report Publication Announcement
2020-11-11 English
Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and Host Conference Call on November 11, 2020
Earnings Release Q3 2020
2020-11-04 English
Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and Host Conference Call on November 11, 2020
Report Publication Announcement
2020-11-04 English
Proxy Statement for the 2020 Annual General Meeting of Shareholders to be held on December 10, 2020
AGM Information
2020-10-30 English
Proxy Statement for the 2020 Annual General Meeting of Shareholders to be held on December 10, 2020
AGM Information
2020-10-30 English
Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021
Regulatory Filings
2020-10-19 English
Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021
Regulatory Filings
2020-10-19 English
Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
Regulatory Filings
2020-10-07 English
Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
Report Publication Announcement
2020-10-07 English
Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19)
Regulatory Filings
2020-09-08 English
Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19)
Report Publication Announcement
2020-09-08 English
Announce Results of KEDRAB in Children
Regulatory Filings
2020-08-19 English
Announce Results of KEDRAB in Children
Report Publication Announcement
2020-08-19 English
Kamada Announces Changes to its Board of Directors
Board/Management Information
2020-08-12 English
Kamada Announces Changes to its Board of Directors
Board/Management Information
2020-08-12 English
Kamada Reports Second Quarter and First Six Months of 2020
Interim / Quarterly Report H1 2020
2020-08-12 English
Kamada Reports Second Quarter and First Six Months of 2020
Report Publication Announcement
2020-08-12 English
Enrollment of First Patient in its Phase 1/2 Clinical Trial of its Plasma-Derived Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) in Israel
Regulatory Filings
2020-08-10 English
Enrollment of First Patient in its Phase 1/2 Clinical Trial of its Plasma-Derived Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) in Israel
Regulatory Filings
2020-08-10 English
Kamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020
Regulatory Filings
2020-08-05 English
Kamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020
Report Publication Announcement
2020-08-05 English
Kamada Announces Availability of its Plasma-Derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19) for Compassionate Use Treatment in Israel
Regulatory Filings
2020-06-17 English
Kamada Announces Availability of its Plasma-Derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19) for Compassionate Use Treatment in Israel
Report Publication Announcement
2020-06-17 English
Kamada Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Progress
Earnings Release Q1 2020
2020-05-18 English
Kamada Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Progress
Report Publication Announcement Q1 2020
2020-05-18 English
Kamada to Announce First Quarter Ended March 31, 2020 Financial Results and Host Conference Call on May 18, 2020
Regulatory Filings
2020-05-11 English
Kamada to Announce First Quarter Ended March 31, 2020 Financial Results and Host Conference Call on May 18, 2020
Regulatory Filings
2020-05-11 English
KamadaandKedrionBiopharmaAnnounceGlobalCollaborationfortheDevelopment,Manufacturingand DistributionofaPlasma-DerivedAnti-SARS-CoV-2(COVID-19) PolyclonalImmunoglobulinProduct
Regulatory Filings
2020-04-27 English
KamadaandKedrionBiopharmaAnnounceGlobalCollaborationfortheDevelopment,Manufacturingand DistributionofaPlasma-DerivedAnti-SARS-CoV-2(COVID-19) PolyclonalImmunoglobulinProduct
Report Publication Announcement
2020-04-27 English
Results of the Extraordinary General Meeting of Shareholders held on March 25, 2020
AGM Information
2020-03-25 English
Results of the Extraordinary General Meeting of Shareholders held on March 25, 2020
Declaration of Voting Results & Voting Rights Announcements
2020-03-25 English
amendment No.1 to the annual report on Form 20-F for the fiscal year ended December 31, 2019
Regulatory Filings
2020-03-16 English
amendment No.1 to the annual report on Form 20-F for the fiscal year ended December 31, 2019
Report Publication Announcement
2020-03-16 English
Kamada Provides Update on Progress Related to its Proprietary Hyper-Immunoglobulin (IgGs) Platform Technology including its Commercial Anti-Rabies IgG and its Pipeline Products Anti-Corona (COVID-19)
Regulatory Filings
2020-03-11 English
Kamada Provides Update on Progress Related to its Proprietary Hyper-Immunoglobulin (IgGs) Platform Technology including its Commercial Anti-Rabies IgG and its Pipeline Products Anti-Corona (COVID-19)
Report Publication Announcement
2020-03-11 English
FORM 6-K, It has filed its Annual Report for the Year Ended December 31, 2019
Report Publication Announcement
2020-02-26 English
FORM 6-K, It has filed its Annual Report for the Year Ended December 31, 2019
Report Publication Announcement FY 2019
2020-02-26 English
FORM 20-F
Annual Report FY 2019
2020-02-26 English
FORM 20-F
Report Publication Announcement
2020-02-26 English
6K: Kamada notice and Proxy Statement for the Extraordinary General Meeting of Shareholders to be held on March 25, 2020
Proxy Solicitation & Information Statement
2020-02-13 English
6K: Kamada notice and Proxy Statement for the Extraordinary General Meeting of Shareholders to be held on March 25, 2020
AGM Information
2020-02-13 English
Financial Results for Fourth Quarter and Fiscal Year 2019
Earnings Release FY 2019
2020-02-12 English
Financial Results for Fourth Quarter and Fiscal Year 2019
Report Publication Announcement
2020-02-12 English
Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2019 Financial Results and Host Conference Call on February 12, 2020
Report Publication Announcement
2020-02-05 English
Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2019 Financial Results and Host Conference Call on February 12, 2020
Report Publication Announcement
2020-02-05 English
Kamada Announces $25 Million Private Placement with FIMI Opportunity Fund
Regulatory Filings
2020-01-21 English
Kamada Announces $25 Million Private Placement with FIMI Opportunity Fund
Share Issue/Capital Change
2020-01-21 English
Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2019 and Provides Full-Year 2020 Revenue Guidance
Earnings Release Q4 2019
2020-01-07 English
Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2019 and Provides Full-Year 2020 Revenue Guidance
Report Publication Announcement
2020-01-07 English